ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Rhea-AI Summary

ADC Therapeutics (NYSE: ADCT) granted options to purchase an aggregate of 49,400 common shares to two new employees on May 1, 2026 as material inducements under its Inducement Plan.

The Compensation Committee approved the grants, made under the NYSE employment inducement exemption (Rule 303A.08). Vesting is 25% at the first anniversary, then 1/48th monthly thereafter, with full vesting at the fourth anniversary subject to continued employment.

News Market Reaction – ADCT

+1.32%

+1.32% Session close to close

In the May 1 session, ADCT gained 1.32%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details option grants for 49,400 shares to new hires under ADCT’s Inducement Plan,...

Analysis

This announcement details option grants for 49,400 shares to new hires under ADCT’s Inducement Plan, vesting over four years and relying on NYSE Rule 303A.08. It adds incrementally to equity-based compensation against a backdrop of existing resale registrations and warrants for 9,834,776 shares. Investors may track how ongoing equity awards, warrant exercises, and registered resales interact with cash needs and the company’s stated runway into at least 2028.

Key Figures

Current share price: $3.765 Inducement options granted: 49,400 options Vesting cliff: 25% +5 more

8 metrics

Current share price $3.765 Pre-news last close for ADCT

Inducement options granted 49,400 options Aggregate options to two new employees on May 1, 2026

Vesting cliff 25% Vests on first anniversary of grant date

Ongoing vesting rate 1/48th monthly Monthly vesting after first anniversary until year four

Full vesting timeline 4 years Entire award vested by fourth anniversary, employment-contingent

Registered warrant shares 9,834,776 shares Shares issuable upon exercise of HCR warrants under S-3/424B3

Potential warrant proceeds $37.5 million Maximum cash to company if all HCR warrants exercised

Shares registered for resale 27,726,052 shares Common shares remaining registered for resale as of Apr 15, 2026 prospectus

Historical Context

5 past events · Latest: Apr 27 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 27	Earnings call notice	Neutral	-4.6%	Announcement of date and time for Q1 2026 results call and webcast.
Apr 01	Inducement grant	Neutral	-0.5%	Grant of 17,000 options to a new employee under NYSE Rule 303A.08 inducement plan.
Mar 10	Earnings & update	Positive	+13.5%	Q4 and 2025 results with ZYNLONTA revenue, cash of $261.3M and runway into 2028.
Mar 03	Earnings call notice	Neutral	-3.1%	Scheduling of Q4 and FY 2025 results call and webcast with operational updates.
Mar 02	Inducement grant	Neutral	-3.1%	Grant of 135,000 options to three new employees under the Inducement Plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Historically, ADCT’s stock tended to move more on substantive financial/clinical updates, while routine items like conference-call notices and inducement grants saw modest, often negative drift.

Recent Company History

Over the last few months, ADCT has mixed operational, financial, and administrative news. Inducement grants like those on March 2, 2026 and April 1, 2026 led to small negative moves. In contrast, full-year 2025 results on March 10, 2026 with $73.6M product revenue, $261.3M cash, and a runway at least into 2028 coincided with a +13.48% reaction. Conference-call announcements around earnings saw moderate downside. Today’s inducement grants fit the administrative pattern.

Key Terms

antibody drug conjugates, options, inducement plan, employment inducement exemption

4 terms

antibody drug conjugates medical

"a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs)"

Antibody drug conjugates are targeted medicines that combine an antibody, which seeks out specific markers on diseased cells, with a powerful drug that is released only when the antibody binds its target. Think of it as a guided missile that delivers a toxic payload directly to its target, reducing damage to healthy cells; investors watch them because successful ADCs can offer high-value, niche treatments and drive strong revenue and patent-based protection for developers.

options financial

"made grants of options to purchase an aggregate of 49,400 of the Company's common shares"

Options are contracts that give investors the right to buy or sell an asset at a specific price within a certain time frame. They function like a reservation or a ticket that allows for potential profit or protection against price changes, making them useful tools for managing investment risks or speculating on market movements.

View in glossary

inducement plan financial

"pursuant to the Company's Inducement Plan to motivate and reward the recipients"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

employment inducement exemption regulatory

"made in reliance on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08"

An employment inducement exemption is a regulatory allowance that lets a public company grant stock or option awards to a new hire without getting prior shareholder approval, provided the awards are given solely to attract or retain that employee and meet specific limits and rules. Investors care because these one-off grants increase the total number of shares available and can dilute existing ownership and earnings per share, much like adding more slices to an already shared pie.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LAUSANNE, Switzerland, May 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 49,400 of the Company's common shares to two new employees on May 1, 2026 (each, a "Grant").

The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08.

The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.

About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl).

ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.

Headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at adctherapeutics.com and follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the timing of the PFS events and topline data release for LOTIS-5 and the results of the trial, the timing for the sBLA submission, acceptance and outcome of review of the sBLA submission, and full FDA approval; the Company's ability to grow ZYNLONTA® revenue in the United States and potential peak revenue; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented by the Company on December 3, 2025, the timing, publication and outcome of the full LOTIS-7 trial, compendia inclusion and regulatory strategy and the commercial opportunity; expected cash runway at least to 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's clinical trials; the timing, publication and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including HealthCare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness, the impact on our future revenue streams, and the significant cash required to service such indebtedness; the impact, if any, from the amendment to the agreement with HealthCare Royalty Management and our strategic alternatives; the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities; and the uncertainties of international trade policies, including tariffs, sanctions, trade barriers and most favored nation drug pricing and the potential impact they may have on our business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.

CONTACTS:
Investors and Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com 
+1 862-926-9040

View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-302759546.html

SOURCE ADC Therapeutics SA

FAQ

Did ADC Therapeutics (ADCT) grant stock options on May 1, 2026?

Yes. ADC Therapeutics granted options for 49,400 common shares to two new employees on May 1, 2026. According to the company, the awards were approved by the Compensation Committee under the Inducement Plan and issued as material inducements using the NYSE exemption.

What is the vesting schedule for the ADCT inducement grants?

The grants vest 25% on the first anniversary, then 1/48th of the aggregate award monthly thereafter until year four. According to the company, continued employment is required and full vesting is reached on the fourth anniversary of the May 1, 2026 grant date.

How many employees received options and what was the total size of the ADCT grants?

Two new employees received a combined total of 49,400 options to purchase common shares on May 1, 2026. According to the company, the grants were offered as material inducements and approved by the Compensation Committee under the Inducement Plan.

Do the ADCT inducement grants require shareholder approval or cause dilution?

The company issued the options under its Inducement Plan without reporting shareholder approval in this release. According to the company, grants relied on NYSE Rule 303A.08; actual dilution depends on future exercise and outstanding share count, which the release does not quantify.

Where can investors find the full details of the ADCT inducement grants?

Investors can find details in the company's May 1, 2026 release and related regulatory filings. According to the company, the disclosure includes grant size, recipients, vesting schedule, Compensation Committee approval, and reliance on NYSE Rule 303A.08.